This @JAMADerm editorial discusses a novel risk stratification system for cutaneous squamous cell carcinoma that was developed using a retrieval augmented generation–enabled large language model. ja.ma/445Wzzb

Role of CTCF in #cscc progression

Most viewed this week from @JAMAOnc: ICIs can treat advanced cancers in solid organ transplant recipients, especially cSCC, but overall survival is limited, and mTOR inhibitors with steroids may reduce rejection risk. ja.ma/4eJFcYN

An in-depth look at the involvement of kindlin-1 in cutaneous squamous cell carcinoma (SCC). 👀 Drs. Carrasco, Brunton, and colleagues at @EdinCRC provide evidence that Kindlin-1 loss 🚫 in SCC can promote invasion through the upregulation of MMP13. 🔗 go.nature.com/3zz41G5

New Post! Thank you to Dr. Michael Baddour, Head & Neck Surgeon at Emory University, who composed this expert review of the importance of understanding perineural spread in cutaneous squamous cell carcinomas of the head and neck. #AHNSSkin @AHNSinfo ow.ly/1c9150SzPYB

What differentiate $MDNAF from other #IL2 is "Durability" Many are asking me, why $HOWL is down so much despite the CR they had in Cutaneous SCC? So I went back to $HOWL slides & looking deeper into the slide while focusing ONLY on the high dose (disregard all the lower dose from dose escalation) we can see the 2 PR's patients went back to "Progressive Disease" 8 weeks from getting PR! Many patients on the high dose >12mg/kg progressed after 8 - 16 weeks! On the other hand, $MDNA.to show that all patients who had a clinical activity had a longer period of time on the drug, including a 2 years PDAC patient 100% free!

⚠️#Hydrochlorothiazide: #cutaneous_squamous_cell_carcinoma (SCC) ☀️In a case-control study, Hydrochlorothiazide users had a 2- to 7-fold increased risk of cutaneous #SCC, with a clear dose-response effect. 😎Patient education on #Sun_avoidance & #Sun_protection is recommended.

Very valuable overview and interrogation of data. Great work Lee Lab! @Stanford @StanfordMed @BencomoTomas @CarolynLeeMDPhD Gene expression landscape of cutaneous squamous cell carcinoma progression academic.oup.com/bjd/article…

Our first 25 metastatic cSCC WGS 90X/30X. Plenty to explore including clinical data. Thanks again to our generous patients who allowed us access to their tumours.

Hey mate, this is awesome. I am a B.I. Administrator, with a broad experience in IT from dev/coding to testing to DB work. Happy to discuss offline. :-) I am also currently battling stage 4 metastatic cutaneous scc. I am doing what I can where I can to fight it. Or help out where I can. The only thing holding back the cancer inside my body is an experimental drug where I am part of a clinical trial. Again, happy to discuss offline. Please DM me, Many thanks in advance, mate! 🙏🙏

Limitations of the Commercially Available Gene Expression Test in Predicting Cutaneous Squamous Cell Carcinoma Metastasis and Clinical Outcomes - Journal of the American Academy of Dermatology jaad.org/article/S0190-9622%…

With the advent of RNA-based medicine, PVT1 may be a promising molecular target for the management of inoperable or metastatic cutaneous squamous cell carcinoma (cSCC). Increased expression of PVT1 may serve as a biomarker for cSCCs. doi.org/10.1093/bjd/ljad419

Extrachromosomal DNA in cutaneous squamous cell carcinoma is associated with increased nodal disease biorxiv.org/content/10.1101/…

My 1st first author preprint is out! @CarolynLeeMDPhD and I analyzed public RNA-Seq data from 147 cutaneous squamous cell carcinoma (cSCC) samples to create a set of robust differentially expressed genes (DEGs) involved in cSCC pathogenesis biorxiv.org/content/10.1101/… 🧵 below! /1

Expected changes in the Cutaneous Squamous Cell Carcinoma (cSCC) market are driven by improved diagnostics, heightened disease awareness, & upcoming therapy introductions. Learn more about the key factors that profoundly alter the cSCC market dynamics: tinyurl.com/y23v2khw.

PI3K and CDK inhibitors combo against advanced cutaneous squamous cell carcinoma. mdpi.com/2072-6694/16/2/370

Heading in to #ESMO23 ☀️ 😎 to present updated survival results for the phase 2 trial of #neoadjuvant #immunotherapy in resectable cutaneous #squamous #skin #cancer #cSCC @SquamousCscc @NEJM @AHNSinfo @Regeneron @MDAndersonNews

Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic #SkinCancer with high mortality rates. @ElinaSiljamaki et al. identify PLX8394 as a potential therapeutic compound for advanced and metastatic cSCC. 👉nature.com/articles/s41388-0…

PD-1-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) ineligible for surgery or radiation. But some patients don’t respond or have severe immune-related adverse events. There is a need for improved therapies. 2/11

Glad to share our collaborative paper with the group of andor.pivarcsi@imbim.uu.se on lncRNA PVT1 in cSCC Long non-coding RNA PVT1 is overexpressed in cutaneous squamous cell carcinoma and exon 2 is critical for its oncogenicity academic.oup.com/bjd/article…